Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate vs propofol sedation in postoperative moderate/severe craniocerebral injury
ChiCTR2200059089Phase 4Recruiting
- Sponsor
- Tianshui First People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in traumatic brain injury (TBI) and Neurocritical illness comparing Remimazolam besylate + remifentanil with Propofol + remifentanil (2 arms). Primary endpoints: Richmond Agitation-Sedation Scale (RASS), Time of mechanical ventilation and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
remimazolampropofol
03
Conditions
traumatic brain injury (TBI)Neurocritical illness
Beyond the preview
Go deeper on ChiCTR2200059089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059089.